Table 1 Baseline characteristics of the 2200 participants who received continuous renal replacement therapy in multiple medical centers.
Variable | Total (n = 2200) | SMA/BMI | ||||
|---|---|---|---|---|---|---|
Q1 [0.99–3.93] | Q2 [3.93–4.76] | Q3 [4.76–5.58] | Q4 [5.58–9.76] | p value | ||
Sex, n (%) | ||||||
Male | 1318 (59.9) | 109 (19.8) | 263 (47.8) | 441 (80.2) | 505 (91.8) | < 0.001 |
Female | 882 (40.1) | 441 (80.2) | 287 (52.2) | 109 (19.8) | 45 (8.2) | |
Age, n (%) | ||||||
18–34 | 83 (3.8) | 19 (3.5) | 18 (3.3) | 19 (3.5) | 27 (4.9) | < 0.001 |
35–49 | 220 (10.0) | 28 (5.1) | 54 (9.8) | 69 (12.5) | 69 (12.5) | |
50–64 | 570 (25.9) | 94 (17.1) | 127 (23.1) | 153 (27.8) | 196 (35.6) | |
65–98 | 1327 (60.3) | 409 (74.4) | 351 (63.8) | 309 (56.2) | 258 (46.9) | |
BMI, n (%) | ||||||
< 25 | 1465 (66.6) | 255 (46.4) | 376 (68.4) | 399 (72.5) | 435 (79.1) | < 0.001 |
25–29 | 576 (26.2) | 208 (37.8) | 136 (24.7) | 130 (23.6) | 102 (18.5) | |
≥ 30 | 159 (7.2) | 87 (15.8) | 38 (6.9) | 21 (3.8) | 13 (2.4) | |
AKI cause, n (%) | ||||||
Septic | 1295 (58.9) | 339 (61.6) | 350 (63.6) | 325 (59.1) | 281 (51.1) | < 0.001 |
Nephrotoxin | 93 (4.2) | 23 (4.2) | 16 (2.9) | 28 (5.1) | 26 (4.7) | |
Ischemia | 343 (15.6) | 70 (12.7) | 74 (13.5) | 104 (18.9) | 95 (17.3) | |
Post-op | 162 (7.4) | 41 (7.5) | 34 (6.2) | 35 (6.4) | 52 (9.5) | |
Volume control | 75 (3.4) | 20 (3.6) | 17 (3.1) | 12 (2.2) | 26 (4.7) | |
Others | 232 (10.5) | 57 (10.4) | 59 (10.7) | 46 (8.4) | 70 (12.7) | |
Comorbidity, n (%) | ||||||
Hypertension | 838 (38.1) | 259 (47.1) | 215 (39.1) | 195 (35.5) | 169 (30.7) | < 0.001 |
Diabetes | 788 (35.8) | 219 (39.8) | 205 (37.3) | 195 (35.5) | 169 (30.7) | 0.014 |
Any tumor | 793 (36.0) | 184 (33.5) | 209 (38.0) | 225 (40.9) | 175 (31.8) | 0.006 |
Metastatic solid tumor | 152 (6.9) | 42 (7.6) | 45 (8.2) | 38 (6.9) | 27 (4.9) | 0.154 |
Myocardial infarction | 195 (8.9) | 48 (8.7) | 48 (8.7) | 56 (10.2) | 43 (7.8) | 0.582 |
Congestive heart failure | 330 (15.0) | 85 (15.5) | 78 (14.2) | 89 (16.2) | 78 (14.2) | 0.736 |
Peripheral vascular disease | 175 (8.0) | 45 (8.2) | 47 (8.5) | 39 (7.1) | 44 (8.0) | 0.834 |
Peptic ulcer disease | 123 (5.6) | 39 (7.1) | 33 (6.0) | 28 (5.1) | 23 (4.2) | 0.183 |
Biochemical data, mean (SD) | ||||||
Hemoglobin (g/dL) | 9.5 (2.2) | 9.4 (2.1) | 9.4 (2.1) | 9.6 (2.4) | 9.6 (2.4) | 0.148 |
Albumin, (g/dL) | 2.7 (0.7) | 2.7 (0.6) | 2.6 (0.7) | 2.7 (0.6) | 2.8 (0.7) | 0.004 |
PT INR | 2.7 (4.4) | 2.7 (3.9) | 3.3 (5.6) | 2.5 (3.6) | 2.6 (4.2) | 0.016 |
CRP (mg/dL) | 12.8 (10.9) | 14.2 (11.6 | 13.2 (10.6) | 12.4 (10.9) | 11.5 (10.5) | < 0.001 |
Stay length (day), mean (SD) | ||||||
Hospital | 40.0 (62.0) | 40.3 (70.3) | 39.4 (62.2) | 41.2 (61.7) | 39.2 (53.0) | 0.951 |
ICU | 14.7 (28.5) | 15.4 (26.4) | 13.1 (24.9) | 16.4 (36.9) | 13.8 (23.7) | 0.229 |
Mechanical ventilation, n (%) | 1555 (70.7) | 386 (70.1) | 390 (71.0) | 398 (72.3) | 381 (69.3) | 0.746 |
CRRT duration (day), mean (SD) | 7.12 (12.5) | 6.3 (11.4) | 6.5 (13.1) | 8.4 (13.5) | 7.2 (11.9) | 0.028 |
CRRT setting, mean (SD) | ||||||
Prescribed dose (mL/kg/h) | 42.5 (19.6) | 40.7 (18.9) | 44.3 (21.3 | 43.1 (20.8 | 41.7 (17.2 | 0.014 |
Blood flow rate (mL/min) | 114.4 (25.7) | 113.8 (26.0) | 115.4 (26.9 | 113.0 (23.9 | 115.5 (26.1 | 0.288 |
Dialysate flow rate (mL/h) | 1184.9 (442.2) | 1162.6 (449.7) | 1205.3 (469.4) | 1219.9 (462.0 | 1151.7 (379.2 | 0.028 |
Replacement flow rate (mL/h) | 961.7 (584.7) | 956.2 (581.8) | 949.0 (570.4) | 969.2 (610.4 | 972.4 (576.6 | 0.901 |
Charlson comorbidity index, n (%) | ||||||
0 | 305 (13.9) | 73 (13.3) | 59 (10.7) | 71 (12.9) | 102 (18.5) | 0.001 |
1–5 | 1452 (66.0) | 360 (65.5) | 370 (67.3) | 362 (65.8) | 360 (65.5) | |
6–10 | 398 (18.1) | 104 (18.9) | 101 (18.4) | 108 (19.6) | 85 (15.5) | |
11–17 | 45 (2.0) | 13 (2.4) | 20 (3.6) | 9 (1.6) | 3 (0.5) | |
APACHE II score, mean (SD) | 27.3 (7.9) | 27.4 (7.7) | 27.7 (7.8) | 27.3 (7.6) | 26.7 (8.4) | 0.261 |
SOFA score, mean (SD) | 11.4 (3.5) | 11.1 (3.4) | 11.3 (3.3) | 11.5 (3.6) | 11.1 (3.6) | 0.414 |
